The spontaneous neoantigen-specific CD4 <sup>+</sup> T-cell response to a growing tumor is functionally and phenotypically diverse
These findings offer unprecedented insight into the functional diversity of a natural neoantigen-specific CD4<sup>+</sup> T-cell response and show how immunotherapeutic intervention influences the phenotype, magnitude, and efficacy of the antitumor immune response. This information could lead to new approaches to immune monitoring in the clinical setting of checkpoint blockade immunotherapy and cancer vaccines. Furthermore, we show that Treg can be a potent source of TCRs that can mediate therapeutic benefit in the setting of ACT.
Authors
- Ezra E.W. Cohen (ORCID: https://orcid.org/0000-0002-9872-6242)
- Rukman R. Thota (ORCID: https://orcid.org/0000-0002-9225-9516)
- Stephen Philip Schoenberger (ORCID: https://orcid.org/0000-0002-9870-7340)
- Martin S. Naradikian (ORCID: https://orcid.org/0009-0000-1745-420X)
- Bjoern Peters (ORCID: https://orcid.org/0000-0002-8457-6693)
- Pandurangan Vijayanand
- Spencer E. Brightman (ORCID: https://orcid.org/0000-0002-9930-7218)
- Ryan Q. Griswold
- Suzie Alarcón
- Aaron M. Miller (ORCID: https://orcid.org/0000-0002-9563-4174)
- Karla Soria Zavala
- Hannah Dose
- Manuel Azaid Ordaz-Arias
- Navid Djassemi
Institutions
- La Jolla Institute for Immunology (US)
- UC San Diego Health System (US)
- University of California San Diego (US)
- General Atomics (United States) (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/jitc-2025-012209
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- National Institutes of Health
- National Cancer Institute